CLINICAL TRIALS PROFILE FOR ALBACONAZOLE
✉ Email this page to a colleague
Clinical Trials for Albaconazole
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00199264 ↗ | Efficacy Vulvovaginitis Candida | Terminated | J. Uriach and Company | Phase 2 | To compare the therapeutic efficacy of 10 mg, 40 mg, 80 mg, 160 mg and 320 mg of albaconazole, as a single oral dose, in women affected by acute non-complicated vulvovaginitis due to Candida spp. |
| NCT00509275 ↗ | A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP) | Completed | GlaxoSmithKline | Phase 1 | In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately 11 centres in the USA, Canada and Australia. The primary objective of the study is to assess the patient response to three W0027 regimens in subjects with MTTP. Secondary objectives include assessment of the safety, tolerability and skin and nail pharmacokinetics to the three Albaconazole regimens. |
| NCT00509275 ↗ | A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis (MTTP) | Completed | Stiefel, a GSK Company | Phase 1 | In this phase Ib, multi-centre, randomized, double-blind, placebo-controlled parallel group study, 120 subjects with moccasin type tinea pedis (MTTP) will be enrolled at approximately 11 centres in the USA, Canada and Australia. The primary objective of the study is to assess the patient response to three W0027 regimens in subjects with MTTP. Secondary objectives include assessment of the safety, tolerability and skin and nail pharmacokinetics to the three Albaconazole regimens. |
| NCT00730405 ↗ | Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis | Completed | GlaxoSmithKline | Phase 2 | Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus. |
| NCT00730405 ↗ | Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis | Completed | Stiefel, a GSK Company | Phase 2 | Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus. |
| NCT01014962 ↗ | A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus | Completed | GlaxoSmithKline | Phase 1 | The purpose of this study is to determine an upper dose of albaconzole to be administered in a Thorough QTc study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Albaconazole
Condition Name
Clinical Trial Locations for Albaconazole
Trials by Country
Clinical Trial Progress for Albaconazole
Clinical Trial Phase
Clinical Trial Sponsors for Albaconazole
Sponsor Name
